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ABSTRACT 
Background: We compare, through the European Liver Transplant Registry, long-
term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus 
immediate-release-tacrolimus (IR-T)-based immunosuppression. This retrospective 
analysis comprises up to 8-year data collected 2008–2016, in an extension of our 
previously-published study.  
Methods: Patients with <1 month follow-up were excluded; patients were propensity 
score-matched for baseline characteristics. Efficacy measures included: 
univariate/multivariate analyses of risk factors influencing graft/patient survival up to 
8-years post-transplantation; graft/patient survival up to 4 years with PR-T versus IR-
T. Overall, 13,088 patients were included from 44 European centers; propensity-
score-matched analyses comprised 3006 patients (PR-T: n=1002; IR-T: n=2004).  
Results: In multivariate analyses, IR-T-based immunosuppression was associated 
with reduced graft survival (risk-ratio: 1.49; p=0.0038) and patient survival (risk-ratio: 
1.40; p=0.0215). There was improvement with PR-T versus IR-T in graft survival 
(83% vs 77% at 4 years, respectively; p=0.005) and patient survival (85% vs 80%; 
p=0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft 
survival rate versus patients receiving IR-T at last follow-up (p<0.001), or started and 
maintained on PR-T (p=0.019). One graft loss in 4 years was avoided for every 14.3 
patients treated with PR-T versus IR-T.  
Conclusion: PR-T-based immunosuppression might improve long-term outcomes in 
liver transplant recipients versus IR-T. 
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MAIN BODY TEXT 
Introduction 
Significant advances in the success of liver transplantation have been made over the 
last two decades, despite the increasing use of extended-criteria donors.1 However, 
while 1-year graft and patient survival rates in Europe are 77% and 83%, 
respectively, after a first liver transplantation, 10-year graft and patient survival rates 
remain lower, at 54% and 61%.2 Improving long-term liver transplant outcomes has, 
therefore, become a primary focus of the transplant community. Many factors can 
negatively influence outcomes in liver transplantation, including high Model for End-
stage Liver Disease (MELD) scores and the viral status of the recipient (for example, 
hepatitis C virus (HCV) infection).3,4 Non-adherence to immunosuppressive therapy, 
and high intra-patient variability of drug exposure, could also potentially reduce 
long-term transplant outcomes.5–10 
 
Tacrolimus is now the cornerstone of immunosuppression after liver 
transplantation.11 A once-daily, prolonged-release (PR) formulation of tacrolimus was 
licensed in Europe in 2007, for use in adult kidney or liver transplant recipients.12 PR 
tacrolimus has demonstrated comparable efficacy to IR tacrolimus in clinical studies 
with de novo liver transplant recipients, and is efficacious following conversion of 
stable liver transplant recipients from IR to PR tacrolimus.13–16 However, it is thought 
that the PR formulation may offer advantages over twice-daily, immediate-release 
(IR) tacrolimus, by reducing non-adherence to immunosuppressant medication, and 
by decreasing intrapatient variability in tacrolimus exposure.17–19 As both of these 
parameters have been associated with poor liver transplant outcomes,8,20 treatment 
with PR tacrolimus has the potential to improve long-term outcomes for liver 
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recipients, compared with the IR formulation. However, as clinical trials are of 
relatively short duration, there is a need for data to assess the effect of PR 
tacrolimus on long-term outcomes in liver transplantation. In this regard, registry 
studies can provide prospective and retrospective long-term data.  
 
The impact of PR versus IR tacrolimus on long-term graft and patient survival was 
recently assessed using data from the European Liver Transplant Registry (ELTR) in 
528 and 3839 patients receiving PR or IR tacrolimus, respectively.21 The study was 
conducted at 21 European centers between 2008 and 2012.21 Multivariable analyses 
showed that the use of IR tacrolimus was associated with a higher risk of graft loss 
(risk ratio: 1.81; p=0.001) and patient death (risk ratio: 1.72; p=0.004) compared with 
PR tacrolimus.21 We report here an analysis of up to 8-year data, collected between 
2008 and 2016, in an extension of the previously-published study, with the aim of 
comparing long-term liver transplant outcomes with PR versus IR tacrolimus-based 
immunosuppression. We also studied the outcome of converting patients from one 
formulation of the drug to the other, during the post-transplantation follow-up period. 
 
Materials and Methods 
This was a retrospective analysis of primary liver transplant patients receiving PR 
tacrolimus (Advagraf™, Astellas Pharma Europe BV, Netherlands) and IR tacrolimus 
in the ELTR database, as previously described.21 The ELTR currently represents 
liver transplant data from 174 transplant centers across Europe. Data from 
participating centers are collected on a voluntary basis at regular intervals using a 
two-part, standardized questionnaire designed by the ELTR Coordinating 
Committee, to capture information on donors and recipients, as described 
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previously.21 The methods used to populate the registry and obtain the data have 
been described elsewhere.22–24 In order to prevent center bias, only the 44 centers 
who used both PR and IR tacrolimus at the time of the study were eligible for 
inclusion in this analysis. 
 
Inclusion criteria 
Data were collected prospectively from patients (≥18 years old) who underwent their 
first liver transplant between January 2008 and June 2016 from contributing centers 
across Europe. All patients included in this study received PR or IR tacrolimus, with 
or without concomitant immunosuppressants (including induction agents) within the 
first month after liver transplantation.  
 
Clinical efficacy measures  
Efficacy measures were analyzed using the modified intent-to-treat (mITT) 
population, which excluded all patients who had less than 1 month of follow-up after 
transplantation. This strategy aimed to avoid the potential impact of early post-
operative complications not associated with the immunosuppressive regimen. The 
clinical efficacy measures included univariate and multivariate analyses of the risk 
factors influencing graft and patient survival; Kaplan–Meier estimates of the 
incidence of graft and patient survival stratified by PR and IR tacrolimus-based 
immunosuppression; and causes of graft loss and mortality. Treatment groups were 
stratified by PR or IR tacrolimus treatment during the first month after 
transplantation, and patients remained in these allocated groups, regardless of any 
changes in immunosuppression during follow-up. However, cross-over changes from 
IR to PR and vice versa after 1 month of therapy, regardless of the date of 
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change(s), were considered in order to measure their impact on graft and patient 
outcomes. The maintenance immunosuppression data considered in this study were 
those collected at the last patient follow-up. The number of patients needed to treat 
with PR versus IR tacrolimus in order to avoid one graft loss in 4 years was 
calculated. In order to adjust for the number of patients at risk over the enrollment 
time between 2008 and 2016 (less patients at risk in the PR than IR tacrolimus group 
at 4 years owing to the gradual increase in the use of PR tacrolimus), the era of 
transplantation was added to the univariate and multivariate analyses. 
 
Propensity score matching 
In order to account for differences in donor and recipient baseline characteristics 
between groups when estimating the effect of treatment on outcomes, the clinical 
efficacy measures were repeated on a propensity score-matched population. PR and 
IR tacrolimus groups were paired on a 1:2 ratio according to 18 items with similar 
values. The propensity score was based on recipient age (≥60 versus <60 years), 
donor age (≥60 versus <60 years), full-size organ from a donor after brain death 
versus all other alternative grafts (living donor, domino, donation after circulatory 
death, or split grafts from a donor after brain death), MELD score (>24 versus ≤24), 
recipient hepatitis B virus surface antigen (HBsAg), hepatocellular carcinoma (HCC), 
presence of severe ascites before liver transplantation, United Network for Organ 
Sharing (UNOS) status (3–4 versus 1–2), total ischemia time (≥6 versus <6 hours), 
graft preservation solution Histidine Tryptophan Ketoglutarate (HTK) versus all other 
solutions (University Wisconsin [UW], Celsior, IGL-1, Marshall, Ringer, SCOT, or 
other) and administration of other immunosuppressive medications early post 
transplantation (corticosteroids, mycophenolate mofetil (MMF), ciclosporin, 
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basiliximab, daclizumab, sirolimus, everolimus, azathioprine). For continuous 
variables that were converted to discontinuous variables in the model (eg, donor 
age, recipient age, MELD score) the values that were the most discriminant between 
PR and IR tacrolimus were selected as cut-offs, based on calculation of Chi square 
and odds ratios (data not shown). All unmatched units in the PR and IR tacrolimus 
groups were excluded from the propensity score-matched population. 
 
Statistical analyses 
Statistical analyses were conducted as previously described.21 A univariate Cox 
regression analysis was performed to evaluate the risk factors influencing graft and 
patient survival after liver transplantation. Data from the univariate analyses were 
reported using log-rank p values, with p<0.05 considered to be statistically 
significant. A Cox proportional hazards regression evaluation (p<0.15) was used in a 
multivariate model to assess the impact of donor and recipient variables on graft and 
patient survival. Patients with missing data on the ELTR questionnaire were 
excluded from the multivariate analyses. Kaplan–Meier analyses were used to 
estimate graft and patient survival stratified by treatment group; statistical analyses 
were performed using the log–rank test (p<0.05). Analyses were performed using 
SAS® Enterprise Guide version 5.1 (SAS Institute Inc., Cary, North Carolina, USA). 
 
Results 
Donor and recipient characteristics and demographics 
Patient population 
In the initial ELTR study, 4367 primary liver transplant recipients (PR tacrolimus, 
n=528; IR tacrolimus, n=3839) were included in the analysis, between 2008 and 
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2012.21 In this extension analysis, 13,088 primary liver transplant recipients were 
included (Figure 1). All patients received either PR tacrolimus (n=1762) or IR 
tacrolimus (n=11,326). Since PR tacrolimus was licensed for use in 2007,12 the 
proportion of patients who received PR tacrolimus during Month 1 gradually 
increased over enrolment (between 2008 and 2016). 
 
Baseline characteristics 
Baseline characteristics of donors and recipients are presented in Table 1. Mean 
recipient age was greater in the PR versus IR tacrolimus group (52.1±18.7 vs 
51.8±18.1 years, respectively; p<0.001). The other main characteristics and their 
differences between groups are shown in Table 1. 
 
Concomitant medications 
Baseline tacrolimus-associated induction immunosuppressive medications were 
different in the two groups: Corticosteroids (69.2% vs 61.4%, p<0.001), everolimus 
(7.5% vs 2.5%, p<0.001), MMF (75.1% vs 55.8%, p<0.001) and daclizumab (1.8% 
vs 0.8%, p<0.001) were more frequently combined with PR tacrolimus. Azathioprine 
(3.2% vs 0.5%, p<0.001), ciclosporin (1.6% vs 0.2%, p<0.001), basiliximab 25.4% vs 
22.0%, p=0.002) and sirolimus (0.6% vs 0.2%, p=0.026) were more frequently 
combined with IR tacrolimus. However propensity score matching has been used to 
account for these baseline differences (see below). 
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Analyses of patients with ≥1 month of follow-up 
Univariate analyses  
In the univariate analysis, IR tacrolimus during the first month post transplantation 
was identified as a significant risk factor for inferior graft survival (p<0.001) and 
patient survival (p=0.003) over 8 years. Other factors that significantly contributed to 
reduced long-term graft and patient survival are listed in Table 2.  
 
Kaplan–Meier analyses 
Kaplan–Meier analysis demonstrated significantly improved graft and patient survival 
over 4 years with PR versus IR tacrolimus (84% vs 79%, p<0.001 and 85% vs 81%, 
p=0.003, respectively) (Figure 2). At Year 4, a 5% and 4% improvement in graft and 
patient survival, respectively, was observed in the PR versus IR tacrolimus group. 
 
Propensity score-matched analyses  
The propensity score-matched analysis was performed on 3,006 patients (PR 
tacrolimus, n=1,002; IR tacrolimus, n=2,004). Donor and recipient baseline 
characteristics were generally comparable between the two treatment groups for the 
propensity score-matched patients, especially for the concomitant 
immunosuppressive drugs combined with tacrolimus (Table 1). 
 
Univariate and multivariate analyses 
In the univariate analysis, the use of IR tacrolimus was a significant risk factor for 
reduced graft and patient survival (p=0.005 and p=0.017, respectively) in addition to 
other factors listed in Table 3. Long-term graft survival was significantly impacted by 
thirteen additional factors:  donor age ≥50 years (p<0.001), recipient age ≥50 years 
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(p=0.006), recipient dialysis twice in week prior to transplantation (p=0.016), negative 
HBV delta (p=0.017), positive anti-HCV serology (p<0.001), positive HIV serology 
(p=0.028), positive HCV RNA (p<0.001), urgent liver transplant (p=0.038), UNOS 
status 1 or 2 (p<0.001), serum creatinine concentration ≥2 mg/dL (p=0.01), Milan 
criteria-out in patients with HCC (p<0.001), HCC with tumor size >50 mm  (p<0.001) 
and heterotopic liver transplant (p=0.003). 
Long-term patient survival was significantly impacted by fifteen other factors: donor 
age ≥50 years (p<0.001), presence of macro/micro-vesicular graft steatosis 
(p=0.039), male recipient (p=0.021),  recipient age ≥50 years (p=0.001), recipient 
dialysis twice in week prior to transplantation (p=0.006), negative HBV delta 
(p=0.025), positive anti-HCV serology (p<0.001), positive HIV serology (p=0.045), 
positive HCV RNA (p<0.001), UNOS status 1 or 2 (p<0.001), serum creatinine 
concentration ≥2 mg/dL (p=0.001), cancer as main indication (p=0.032), Milan 
criteria-out in patients with HCC (p<0.001), HCC with tumor size >50 mm  (p<0.001) 
and heterotopic liver transplant (p=0.001). 
 
In the multivariate analysis (Table 4), the use of IR tacrolimus was a significant 
independent risk factor for reduced graft survival (risk ratio: 1.49; 95% confidence 
interval (CI): 1.14–1.96; p=0.0038) associated with five other factors:   recipient 
positive anti-HCV serology (risk ratio: 2.05; 95% confidence interval (CI): 1.66–2.54; 
p<0.001), recipient age ≥50 years (risk ratio: 1.74; 95% confidence interval (CI): 
1.43–2.11; p<0.001), UNOS status 1 or 2 (risk ratio: 1.69; 95% confidence interval 
(CI): 1.35–2.11; p<0.001), serum creatinine concentration ≥2 mg/dL (risk ratio: 1.66; 
95% confidence interval (CI): 1.18–2.35; p=0.004) and donor age ≥50 years (risk 
ratio: 1.35; 95% confidence interval (CI): 1.09–1.66; p=0.005). 
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The use of IR tacrolimus was also a significant independent risk factor for reduced 
patient survival (risk ratio: 1.40; 95% CI: 1.05–1.86; p=0.0215) associated with six 
other factors:   recipient positive anti-HCV serology (risk ratio: 1.91; 95% confidence 
interval (CI): 1.52–2.40; p<0.001), serum creatinine concentration ≥2 mg/dL (risk 
ratio: 1.90; 95% confidence interval (CI): 1.33–2.71; p<0.001), UNOS status 1 or 2 
(risk ratio: 1.89; 95% confidence interval (CI): 1.49–2.39; p<0.001), recipient age ≥50 
years (risk ratio: 1.74; 95% confidence interval (CI): 1.41–2.16; p<0.001), HCC as 
primary or secondary disease (risk ratio: 1.35; 95% confidence interval (CI): 1.07–
1.69; p=0.01), and donor age ≥50 years (risk ratio: 1.33; 95% confidence interval 
(CI): 1.07–1.66; p=0.01). 
 
Kaplan–Meier analyses and number of patients needed to treat to avoid one graft 
loss 
Kaplan–Meier analysis demonstrated significantly improved graft and patient survival 
over 4 years with PR versus IR tacrolimus (83% vs 77%, p=0.005 and 85% vs 80%, 
p=0.017, respectively) (Figure 3). At Year 4, a 6% and 5% improvement in graft and 
patient survival respectively, was observed in the PR versus IR tacrolimus group. 
The number of patients needed to treat with PR versus IR tacrolimus in order to 
avoid one graft loss in 4 years was 14.3 patients (95% CI: 9.7–27.3). 
 
Analysis of crossover groups 
In the non-converted patients over the study period, graft and patient survival were 
significantly higher with (induction–last follow-up immunosuppressive regimen 
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available) PR–PR than with IR–IR tacrolimus (88% vs 82% at 4 years, p=0.019 and 
89% vs 83% at 4 years, p=0.047, respectively) (Figure 4). Patients converted from 
IR to PR tacrolimus after 1 month had a significantly higher graft and patient survival 
rate compared with patients who were started on and still receiving PR tacrolimus at 
the last follow-up (92% vs 88% at 4 years, p=0.019 and 94% vs 89% at 4 years, 
p=0.004, respectively) or started on and still receiving IR tacrolimus at the last follow-
up (p<0.001 for both).  
 
Causes of graft loss and mortality  
The most common cause of graft loss was infection in both groups (Table 5). Over 8 
years of treatment, the proportion of patients with bacterial infection that resulted in 
graft loss was higher with PR versus IR tacrolimus (17.2% vs 9.2%, respectively; 
p=0.031) (Table 5). Compared with patients receiving IR tacrolimus, ‘other’ causes 
of graft loss were less frequent in patients receiving PR tacrolimus (p=0.01). 
However, there were no significant differences between groups in the incidence of 
graft loss due to acute or chronic rejection, cardiovascular, or renal causes. 
 
The most common cause of patient mortality was infection in both groups (Table 5). 
The proportion of patients with bacterial infection that resulted in patient death was 
similar with PR and IR tacrolimus (18.3% vs 10.4%, respectively; p=0.057). ‘Other’ 
causes of mortality were less frequent in patients receiving PR versus IR tacrolimus 
(p=0.005). There were no significant differences between treatment groups in the 
proportion of patients with cardiovascular or renal causes of mortality. 
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Discussion 
The initial ELTR study was the first large retrospective registry study in Europe, 
evaluating PR tacrolimus-based immunosuppression in primary liver 
transplantation.21 The study showed that the use of IR tacrolimus was associated 
with a higher risk of graft loss and patient death, compared with PR tacrolimus. 
Additionally, PR tacrolimus significantly improved graft and patient survival over 3 
years post transplantation, compared with the IR formulation.21 However, the cohort 
size was relatively limited, as was the length of follow-up. 
 
This extension to the ELTR study, reporting up to 8-year data from adult primary liver 
transplant recipients, confirmed that PR tacrolimus was associated with improved 
graft and patient survival (over 4 years post transplantation), compared with IR 
tacrolimus. Consistent with Adam et al, IR tacrolimus was an independent risk factor 
for graft loss and mortality over 8 years of treatment.21 In addition to the longer time 
period assessed, the number of patients included in the current study exceeded 
13,000, compared with the 4367 patients included in the initial ELTR study.21 This 
provided enhanced statistical robustness, increasing the reliability of the results. 
 
Univariate and multivariate analyses substantiated the independent prognostic value 
of typical risk factors, including donor age (≥50 years), recipient viral status (HCV-
positivity) and UNOS status 1 or 2 in impairing Month 1 to Year 8 graft and patient 
survival.25,26 As reported by Adam et al,21 IR tacrolimus was also identified in this 
study as a significant predictor of graft loss and patient death in univariate analyses. 
Furthermore, after accounting for differences in baseline characteristics between 
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treatment groups, IR tacrolimus formulation remained a significant predictor of graft 
and patient loss, in both univariate and multivariate analyses. 
 
In the previous ELTR study, improvements in graft and patient survival with PR 
versus IR tacrolimus were observed as early as 3 months after transplantation, and 
continued over 3 years.21 Our current data demonstrate that the survival benefit 
associated with PR tacrolimus continues over 4 years of treatment. Furthermore, 
while improved 3-year patient survival with PR versus IR tacrolimus did not reach 
statistical significance for the unmatched patient cohort in the initial ELTR study,21 
the benefit was statistically significant by Year 4 in our current study. Indeed, there 
was a 5% and 4% graft and patient survival advantage, respectively, by Year 4 with 
the PR versus IR formulation. The difference between the PR and IR groups for graft 
and patient survival rates also seemed to increase with time. 
 
Consistent with data reported in a 4-year follow-up of de novo liver transplant 
recipients from a Phase II study,27 PR tacrolimus was associated with 4-year graft 
and patient survival rates of ~90%. As a complement to our previous study, we also 
evaluated the impact of crossover changes from IR to PR and vice versa after 1 
month of induction therapy with regards to graft and patient outcomes. Both graft and 
patient survival were higher in patients who converted from IR to PR tacrolimus, 
compared with those who received induction PR tacrolimus and were still receiving 
PR tacrolimus at last follow-up. While the cause of this is unclear, the data suggest 
that the use of PR tacrolimus at last follow-up therapy is associated with improved 
outcomes, irrespective of the timing of conversion. The transplant community is now 
interested in identifying whether earlier conversion (<6 months after liver 
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transplantation) from IR to PR tacrolimus is associated with better outcomes than 
conversion >6 months post transplantation.28  
 
The survival advantages observed in patients treated with PR versus IR tacrolimus 
reported at 3 years in Adam et al,21 and at 4 years in this study, were not observed in 
short-term, randomized, controlled trials. For example, Trunečka et al reported 
12-month graft survival rates of 85.3% and 85.6%, and patient survival rates of 
89.2% and 90.8%, with PR and IR tacrolimus, respectively.29 The potential survival 
advantages associated with PR tacrolimus in de novo liver transplant recipients may, 
therefore, not become apparent until beyond 1-year post transplantation.  
 
In an independent Editorial that accompanied the initial ELTR study, Asrani et al30 
considered the potential mechanisms underlying the improvement in long-term graft 
and patient survival with PR versus IR tacrolimus-based immunosuppression. 
Compared with IR tacrolimus, PR formulation reduces variability of tacrolimus 
exposure,19,31 and offers a simpler regimen comprising a single, morning dose,12 
which can improve medication adherence.17,18 Indeed, in an expert literature review, 
improved adherence with treatment is highlighted as a main advantage of PR versus 
IR tacrolimus.28 Given that high intra-patient variability in tacrolimus exposure and 
medication non-adherence have been associated with poor transplant outcomes,8,20 
PR tacrolimus may improve long-term graft and patient survival compared with the 
IR formulation. 
 
As observed in the initial ELTR study,21 the overall proportion of patients with graft 
loss was lower in the PR versus IR tacrolimus group. The reasons for graft loss and 
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mortality were generally comparable between groups in this study and, consistent 
with the previous ELTR study, infections were the most frequent cause.21  
 
In this study, not all factors could be controlled by the transplant team in order to 
improve outcomes. Only the type of preservation solution, the ischemia time, and the 
immunosuppressive regimen used could be altered, as donor and recipient 
characteristics cannot be changed in the MELD allocation system used in most 
countries. Therefore, it is important to consider the numbers of patients needed to 
treat with PR tacrolimus in order to avoid one graft loss. In this study, 14.3 patients 
needed to be treated with PR versus IR tacrolimus in order to avoid one graft loss in 
4 years. These data are consistent with those of Muduma et al, who developed a 
model using UK liver transplant data and showed that, over a 3-year time period, one 
graft would be saved for every 14 patients treated with PR versus IR tacrolimus, with 
minimal impact on costs.32 To place these data in clinical context, 15 patients 
needed to be treated with nicotine replacement therapy for one patient to cease 
smoking,33 20 required treatment with calcium and vitamin D for 3 years to prevent 
one hip fracture,34 23 required treatment with flu vaccine to prevent one flu 
episode,35 and 35 needed primary treatment with statins for 5 years to prevent a 
cardiac event.36  
 
Despite the improvements to our study design and analytical methods, any 
conclusions drawn from our findings must be made within the context of the 
limitations of our study, which have been described in detail previously.21 These 
include the retrospective nature of the study, and the long period over which data 
were collected, which may be associated with changes in clinical practice. 
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Furthermore, our study design carries a risk of bias in terms of patient and treatment 
selection. To control for these differences, propensity score-matching was 
undertaken against a larger number of characteristics compared with the initial ELTR 
study. However, it is recognized that propensity-score matching can only be used to 
balance measured variables and cannot entirely exclude inherent differences, such 
as socioeconomic factors, ethnicity, or other unknown variables. A major limitation 
concerns the lack of data on drug exposure, as the dose and trough levels of 
tacrolimus were not captured in the ELTR; it is also not known which IR tacrolimus 
preparation patients were receiving. Despite these limitations, to our knowledge, we 
report on the largest population of liver transplant recipients to date, comparing the 
impact of PR and IR tacrolimus administration. Furthermore, this analysis builds on 
our previous publication by including a three-fold larger cohort, providing extended 
follow-up, evaluating the impact of crossover between IR and PR tacrolimus therapy, 
and reporting the clinical implication of the results in terms of number needed to treat 
to avoid one graft loss. 
 
Our results, based on up to 8-year data, confirm observations from the initial 3-year 
study,21 that PR tacrolimus-based immunosuppression can improve long-term 
outcomes in liver transplantation compared with IR tacrolimus. Furthermore, IR 
tacrolimus-based immunosuppression is a significant predictor of long-term graft loss 
and patient mortality. Conversion from IR to PR tacrolimus after 1 month was also 
associated with a better outcome compared with maintaining patients on IR 
tacrolimus-based immunosuppression, or starting and maintaining patients on PR 
tacrolimus-based immunosuppression. Importantly, our findings confirm that PR 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 25 
 
tacrolimus continues to provide ongoing benefits for graft and patient survival beyond 
3 years post transplantation. 
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TABLES 
Table 1: Baseline characteristics of donors and liver transplant recipients 
Parameter Category mITT population Propensity score-matched patients* 
PR tacrolimus 
(n=1762)‡ 
IR tacrolimus 
(n=11,326)‡ 
p value† PR tacrolimus 
(n=1002)‡ 
IR tacrolimus 
(n=2004)‡ 
p value† 
Donor characteristics 
Mean (SD) age, years  52.1 (18.7) 
(n=1743) 
51.8 (18.1) 
(n=11,018) 
0.49 53.0 (18.7) 53.5 (18.7)  0.56 
 ≥60 years, n (%) 666 (38.2) 3923 (35.6) 0.035 401 (40.0) 806 (40.2) 0.92 
 ≥65 years, n (%) 486 (27.9) 2933 (26.6) 0.27 294 (29.3) 631 (31.5) 0.23 
 ≥75 years, n (%) 198 (11.4) 1188 (10.8) 0.47 135 (13.5) 284 (14.2) 0.60 
Sex, n (%) 
 
Female 754 (43.3) 4874 (44.5) 0.34 449 (45.0) 876 (44.0) 0.57 
Male 987 (56.7) 6072 (55.5) 548 (55.0) 1117 (56.0) 
Recipient characteristics 
Age at first 
transplant, years 
Mean (SD) 53.7 (11.2) 52.3 (11.6) <0.001 53.1 (11.4) 53.3 (10.8) 0.68 
≥60 years, n (%) 584 (33.1) 3176 (28) <0.001 308 (30.7) 603 (30.1) 0.72 
≥65 years, n (%) 242 (13.7) 1169 (10.3) <0.001 115 (11.5) 223 (11.1) 0.78 
≥70 years, n (%) 31 (1.8) 135 (1.2) 0.048 22 (2.2) 22 (1.1) 0.018 
Sex, n (%) Female 571 (32.4) 3783 (33.4) 0.41 328 (32.7) 623 (31.1) 0.36 
 Male 1191 (67.6) 7542 (66.6) 674 (67.3) 1381 (68.9) 
Mean (SD) BMI, 
kg/m2 
 25.9 (4.7) 
(n=1660) 
25.9 (4.8) 
(n=10,714) 
0.97 25.8 (4.8) 
(n=970) 
25.6 (4.5) 
(n=1934) 
0.20 
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Recipient health status and indication for transplant 
HBsAg, n (%) Negative 1486 (91.1) 9130 (87.9) <0.001 908 (90.6) 1810 (90.3) 0.79 
 Positive 146 (8.9) 1261 (12.1) 94 (9.4) 194 (9.7) 
HBV DNA, n (%) 
  
Negative 422 (92.3) 3613 (89.7) 0.079 316 (92.7) 605 (92.2) 0.80 
 Positive 35 (7.7) 413 (10.3) 25 (7.3) 51 (7.8) 
Co-existing HBV and 
delta virus, n (%) 
Negative 316 (91.9) 1956 (87.3) 0.016 202 (92.7) 373 (86.9) 0.029 
Positive 28 (8.1) 284 (12.7) 16 (7.3) 56 (13.1) 
Anti-HCV serology, n 
(%) 
  
Negative 1230 (76.1) 7798 (75.3) 0.48 762 (77.4) 1431 (72.9) 0.008 
Positive 387 (23.9) 2564 (24.7) 222 (22.6) 532 (27.1) 
HCV RNA, n (%) 
  
Negative 292 (61.9) 2699 (66.8) 0.03 217 (63.8) 466 (63.2) 0.85 
Positive 180 (38.1) 1339 (33.2) 123 (36.2) 271 (36.8) 
HIV serology, n (%) Negative 1179 (98.1) 9821 (98.5) 0.24 825 (97.7) 1805 (98.6) 0.12 
Positive 23 (1.9) 147 (1.5) 19 (2.3) 26 (1.4) 
Main indication for 
transplant, n (%) 
  
  
Acute liver 
disease  
111 (6.4) 631 (5.8) <0.001 62 (6.3) 80 (4.1) 0.046 
Malignant tumors 501 (28.8) 2637 (24.0) 246 (24.9) 511 (25.9) 
Chronic liver 
disease 
1004 (57.7) 6694 (61.0) 600 (60.7) 1224 (62.1) 
Benign tumors 45 (2.6) 244 (2.2) 27 (2.7) 36 (1.8) 
Metabolic 
diseases 
64 (3.7) 583 (5.3) 46 (4.7) 95 (4.8) 
Other 16 (0.9) 178 (1.6) 8 (0.8) 26 (1.3) 
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HCC (primary or 
secondary disease), n 
(%) 
No 1210 (69.1) 8163 (72.5) 0.003 
 
715 (71.4) 1397 (69.7) 0.35 
 Yes 
 
542 (30.9) 
 
3092 (27.5) 
 
287 (28.6) 
 
607 (30.3) 
 
Criteria for first liver transplant 
Liver transplant 
urgency§, n (%)  
Yes 99 (7.0) 701 (7.7) 0.35 65 (9.1) 99 (7.0) 0.093 
No 1309 (93.0) 8346 (92.3)  651 (90.9) 1311 (93.0)  
UNOS status**, n (%) 
  
  
  
1 110 (6.7) 1026 (9.7) <0.001 77 (7.7) 170 (8.5) 0.76 
 2 176 (10.7) 1505 (14.2) 141 (14.1) 272 (13.6) 
3 765 (46.4) 5848 (55.0) 594 (59.3) 1162 (58.0) 
4 596 (36.2) 2245 (21.1) 190 (19.0) 400 (20.0) 
Mean (SD) MELD 
score 
 17.1 (8.5) 
(n=1725) 
17.9 (9.0) 
(n=11,040) 
<0.001 17.6 (8.9) 17.6 (8.8) 0.97 
 
Liver function and baseline laboratory values 
Child-Pugh class, n 
(%)  
  
A 100 (16.2) 899 (14.1) 0.085 73 (16.6) 165 (16.1) 0.82 
 B 279 (45.1) 3166 (49.6) 203 (46.2) 492 (48.0) 
C 240 (38.8) 2322 (36.4) 163 (37.1) 367 (35.8) 
Mean (SD) serum 
creatinine 
concentration, mg/dL  
 1.1 (1.5) 
(n=1742) 
1.2 (3.8) 
(n=11,078) 
0.23 1.1 (1.8) 
(n=999) 
1.1 (0.9) 
(n=1993) 
0.97 
Mean (SD) total 
bilirubin, mg/dL  
 5.7 (8.2) 
(n=1718) 
6.2 (9.0) 
(n=11,038) 
0.032 6.1 (8.6) 
 (n=999) 
5.9 (8.7) 
 (n=1999) 
0.44 
Preservation 
solution, n (%) 
HTK 816 (47.1) 3059 (28.0) <0.001 380 (37.9) 691 (34.5) 0.063 
Other 915 (52.9) 7863 (72.0)  622 (62.1) 1313 (65.5) 
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Induction immunosuppressive regimen 
Corticosteroids, n (%) Yes 1219 (69.2) 6959 (61.4) <0.001 777 (77.5) 1579 (78.8) 0.43 
 No 543 (30.8) 4367 (38.6) 225 (22.5) 425 (21.2) 
Azathioprine, n (%) 
 
Yes 9 (0.5) 358 (3.2) <0.001 7 (0.7) 7 (0.3) 0.18 
 No 1753 (99.5) 10,968 (96.8) 995 (99.3) 1997 (99.7) 
Ciclosporin, n (%) Yes 4 (0.2) 180 (1.6) <0.001 4 (0.4) 10 (0.5) 0.70 
 No 1758 (99.8) 11,146 (98.4) 998 (99.6) 1994 (99.5) 
Everolimus, n (%) 
 
Yes 133 (7.5) 280 (2.5) <0.001 49 (4.9) 128 (6.4) 0.10 
 No 1629 (92.5) 11,046 (97.5) 953 (95.1) 1876 (93.6) 
Basiliximab, n (%) Yes 387 (22.0) 2875 (25.4) 0.002 274 (27.3) 518 (25.8) 0.38 
 No 1375 (78.0) 8451 (74.6) 728 (72.7) 1486 (74.2) 
Sirolimus, n (%) Yes 3 (0.2) 66 (0.6) 0.026 1 (0.1) 1 (0.0) 0.62 
No 1759 (99.8) 11,260 (99.4) 1001 (99.9) 2003 (100.0) 
MMF, n (%) Yes 1323 (75.1) 6316 (55.8) <0.001 762 (76.0) 1504 (75.0) 0.55 
 No 439 (24.9) 5010 (44.2) 240 (24.0) 500 (25.0) 
Daclizumab, n (%) Yes 31 (1.8) 87 (0.8) <0.001 23 (2.3) 47 (2.3) 0.93 
 No 1731 (98.2) 11,239 (99.2) 979 (97.7) 1957 (97.7) 
Mean (SD) length of 
follow-up, months 
 25.6 (21.1) 31.5 (26.0) <0.001 24.4 (19.9) 33.7 (25.4) <0.001 
*Propensity-score matching was based on recipient age (≥60 versus <60 years), donor age (≥60 versus <60 years), full-size organ from a 
donor after brain death versus all other alternative grafts (living donor, domino, donation after circulatory death, or split grafts from a donor after 
brain death), MELD score (>24 versus ≤24), recipient hepatitis B virus surface antigen, HCC, presence of severe ascites before liver 
transplantation, UNOS status (3–4 versus 1–2), total ischemia time (≥6 versus <6 hours), graft preservation solution HTK versus all other 
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35 
solutions (University Wisconsin, Belzer, Celsior, IGL-1, Marshall, Ringer, SCOT, or other) and administration of other immunosuppressive 
medications early post transplantation (corticosteroids, MMF, ciclosporin, basiliximab, daclizumab, sirolimus, everolimus, azathioprine). †p value 
between treatment cohort comparisons. ‡Data were not available for all patients; therefore, percentages are calculated based on available data. 
§Liver transplant urgency was determined by the treating physician, and indicated on the questionnaire by ‘yes’ or ‘no’ tick box. **UNOS status: 
1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function. BMI: body 
mass index; HBsAg: hepatitis B virus surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV: 
human immunodeficiency virus; HTK: Histidine Tryptophan Ketoglutarate; IR, immediate-release; MELD: Model for End-stage Liver Disease; 
mITT: modified intent-to-treat; MMF: mycophenolate mofetil; PR: prolonged-release; SD: standard deviation; UNOS: United Network for Organ 
Sharing 
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Table 2: Univariate analyses of risk factors for reduced graft and patient survival 1, 2, and 4 years post transplantation, after exclusion of 
patients with <1 month of follow-up (mITT population) 
Parameters at first transplantation Category n Survival, % p value* 
1 year 2 years 4 years 
Graft survival       
Immunotherapy during Month 1 PR tacrolimus 1762 93 89 84 <0.001 
IR tacrolimus 11,326 91 86 79 
Donor characteristics 
Donor sex 
  
Female 5628 91 86 79 0.51 
Male 7059 91 87 79 
Donor age ≥50 years 
  
Yes 7272 90 85 77 <0.001 
No 5488 93 89 83 
Donor age ≥60 years 
  
Yes 4589 90 84 76 <0.001 
No 8171 92 88 81 
Macro/micro-vesicular graft steatosis No 3286 93 89 82 0.11 
Yes 2947 91 88 80 
Blood group compatibility 
  
Compatible 794 88 83 77 <0.001 
Iso group 11,983 91 87 80 
Non-compatible 113 77 72 59 
Recipient characteristics 
Recipient sex 
  
Female 4354 92 88 81 <0.001 
Male 8733 91 86 78 
Recipient age ≥50 years Yes 8693 90 86 78 <0.001 
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  No 4395 92 89 82 
Recipient age ≥60 years 
  
Yes 3760 89 85 77 <0.001 
No 9328 92 88 81 
Recipient dialysis (twice in week 
prior)  
Yes 442 81 78 71 <0.001 
No 11,177 92 87 80 
Recipient viral status 
HBsAg 
  
Negative 10,616 91 87 79 0.008 
Positive 1407 94 88 83 
Co-existing HBV and delta virus  
  
Negative 2272 90 85 79 0.001 
Positive 312 96 93 91 
Anti-HCV serology 
  
Negative 9028 92 89 82 <0.001 
Positive 2951 88 82 72 
HIV serology 
  
Negative 11,000 91 87 80 <0.001 
Positive 170 82 71 61 
HCV RNA Negative 2991 92 88 83 <0.001 
Positive 1519 88 83 71 
Criteria for liver transplant 
Liver transplant urgency† Yes 800 89 86 81 0.74 
 No 9655 91 87 80  
UNOS status‡ 
  
  
  
1 1136 87 83 77 <0.001 
2 1681 88 84 78 
3 6613 92 88 80 
4 2841 93 88 80 
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UNOS status‡ 1 or 2  Yes 2817 87 84 78 <0.001 
No 9454 92 88 80 
MELD score ≤14 5571 93 87 79 <0.001 
15–25 4938 92 88 82 
>25 2256 87 83 76 
Liver function and laboratory values 
Recipient Child-Pugh class 
  
  
A 999 92 88 79 0.1 
B 3445 94 90 82 
C 2562 91 88 80 
Serum creatinine concentration 
≥2 mg/dL  
Yes 906 83 79 73 <0.001 
No 11,914 92 88 80 
Indication 
Main indication for transplant 
  
  
Acute liver failure 742 90 86 81 <0.001 
Chronic liver 
disease 
7698 91 87 80 
Metabolic disease 647 90 87 80 
Tumor (benign) 289 94 92 88 
Tumor (malignant) 3138 92 85 76 
Other 194 87 83 79 
Acute liver failure as main disease 
  
Yes 725 90 86 81 0.2 
No 12,282 91 87 79 
Cirrhosis as main disease 
  
Yes 6935 91 87 80 0.9 
No 6072 91 86 79 
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Cancer as main disease 
  
Yes 3133 92 85 76 <0.001 
No 9874 91 87 81 
Milan criteria (in patients with HCC) Yes 1613 93 88 81 <0.001 
No 808 87 76 61 
HCC with tumor size >50 mm Yes 214 82 65 48 <0.001 
No 2228 91 86 76 
Surgical procedure 
Total ischemia time  
  
  
>15 hours 103 90 88 83 0.25 
12–15 hours 623 89 84 78 
6–12 hours 8325 91 87 79 
0–6 hours 2409 92 86 80 
Total ischemia time ≥12 hours Yes 726 89 85 78 0.53 
No 10,734 91 87 79 
Type of graft 
  
  
  
  
Full size (donor 
brain death) 
11,390 91 87 79 0.4 
Domino 89 91 84 70 
Living 520 91 83 75 
Reduced 36 88 88 88 
Split 526 90 88 82 
 After circulatory 
death 
486 93 87 80  
Liver transplant 
  
Heterotopic 15 100 88 72 0.67 
Orthotopic 12,424 91 87 80 
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Patient survival       
Immunotherapy during Month 1 PR tacrolimus 1762 94 90 85 0.003 
IR tacrolimus 11,319 92 88 81 
Donor characteristics 
Donor sex 
  
Female 5623 92 88 81 0.48 
Male 7057 92 88 82 
Donor age ≥50 years 
  
Yes 7268 91 87 79 <0.001 
No 5485 94 90 85 
Donor age ≥60 years 
  
Yes 4587 91 86 78 <0.001 
No 8166 93 89 84 
Macro/micro-vesicular graft steatosis No  3284 94 91 85 0.01 
Yes 2943 92 89 82 
Blood group compatibility 
  
Compatible 793 89 84 78 <0.001 
Iso group 11,977 92 89 82 
Non-compatible 113 80 77 63 
Recipient characteristics 
Recipient sex 
  
Female 4353 93 90 84 <0.001 
Male 8727 92 88 81 
Recipient age ≥50 years 
  
Yes 8689 91 87 80 <0.001 
No 4392 94 91 85 
Recipient age ≥60 years 
  
Yes 3758 90 86 78 <0.001 
No 9323 93 89 83 
Recipient dialysis (twice in week Yes 442 82 79 74 <0.001 
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prior) No 11,170 93 89 83 
Recipient viral status 
HBsAg 
  
Negative 10,612 92 88 82 0.007 
Positive 1406 95 90 85 
Co-existing HBV and delta virus  
  
Negative 2272 91 86 80 <0.001 
Positive 312 96 94 92 
Anti-HCV serology 
  
Negative 9023 93 90 84 <0.001 
Positive 2949 89 84 75 
HIV serology 
  
Negative 10,995 93 89 82 <0.001 
Positive 169 82 74 64 
HCV RNA Negative 2991 93 90 85 <0.001 
Positive 1518 90 84 74 
Criteria for liver transplant 
Liver transplant urgency† Yes 800 90 88 86 0.43 
 No 9648 93 89 82  
UNOS status‡ 
  
  
  
1 1135 88 85 81 <0.001 
2 1680 89 85 80 
3 6612 94 90 82 
4 2837 94 90 83 
UNOS status‡ 1 or 2  Yes 2815 88 85 80 <0.001 
No 9449 94 90 83 
MELD score ≤14 5569 94 89 81 <0.001 
15–25 4934 93 90 84 
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>25 2255 88 85 79 
Liver function and laboratory values 
Recipient Child-Pugh class 
  
  
A 999 95 90 82 0.05 
B 3442 95 91 85 
C 2560 92 89 84 
Serum creatinine concentration 
≥2 mg/dL  
Yes 905 84 80 75 <0.001 
No 11,908 93 89 82 
Indication 
Main indication for transplant 
  
  
Acute liver failure 742 90 87 85 <0.001 
Chronic liver 
disease 
7694 92 89 82 
Metabolic disease 647 91 88 82 
Tumor (benign) 289 95 94 91 
Tumor (malignant) 3138 93 86 77 
Other 194 89 86 80 
Acute liver failure as main disease 
  
Yes 725 90 87 85 0.16 
No 12,275 92 88 81 
Cirrhosis as main disease 
  
Yes 6931 92 89 82 0.63 
No 6069 93 88 81 
Cancer as main disease 
  
Yes 3133 93 86 77 <0.001 
No 9867 92 89 83 
Milan criteria (in patients with HCC) Yes 1613 94 89 83 <0.001 
No 808 88 77 62 
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HCC with tumor size >50 mm Yes 214 82 66 50 <0.001 
No 2228 93 87 78 
Total ischemia time  
  
  
>15 hours 103 90 88 85 0.59 
12–15 hours 622 91 87 81 
6–12 hours 8319 92 89 82 
0–6 hours 2409 93 88 82 
Total ischemia time ≥12 hours Yes 725 91 87 81 0.94 
No 10,728 92 88 82 
Type of graft 
  
  
  
  
Full size (donor 
brain death) 
11,387 92 88 81 0.005 
Domino 89 91 87 73 
Living 520 92 84 78 
Reduced 36 100 96 96 
Split 526 93 90 86 
 After circulatory 
death 
482 96 91 85  
Liver transplant 
  
Heterotopic 15 100 88 72 0.5 
Orthotopic 12,417 92 89 82 
*Log-rank p value for effect over 8 years. †Liver transplant urgency was determined by the treating physician, and indicated on the 
questionnaire by ‘yes’ or ‘no’ tick box. ‡UNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous 
medical care, 4. At home with normal function. HBsAg: hepatitis B virus surface antigen; HBV: hepatitis B virus; HCC: hepatocellular 
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carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IR: immediate-release; MELD: Model for End-stage Liver Disease; 
mITT: modified intent-to-treat; PR: prolonged-release; UNOS: United Network for Organ Sharing  
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Table 3: Univariate analyses of risk factors for reduced graft and patient survival for propensity score-matched patients 
Parameters at first transplant Category n Survival, % p value* 
1 year 2 years 4 years 
Graft survival       
Immunotherapy during Month 1 PR tacrolimus 1002 93 89 83 0.005 
IR tacrolimus  2004 90 86 77 
Donor characteristics 
Donor sex 
  
Female 1325 92 87 79 0.55 
Male 1665 91 88 80 
Donor age ≥50 years 
  
Yes 1776 90 85 76 <0.001 
No 1230 93 90 84 
Donor age ≥60 years 
  
Yes 1207 90 84 75 <0.001 
No 1799 92 89 82 
Macro/micro-vesicular graft steatosis No  597 93 90 81 0.069 
Yes 604 90 86 77 
Blood group compatibility 
  
Compatible 182 85 81 74 0.19 
Iso group 2799 92 88 79 
Non-compatible 23 85 77 77 
Recipient characteristics 
Recipient sex 
  
Female 951 92 88 80 0.064 
Male 2055 91 87 78 
Recipient age ≥50 years 
  
Yes 2065 91 86 77 0.006 
No 941 93 89 83 
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Recipient age ≥60 years 
  
Yes 911 90 85 76 0.016 
No 2095 92 88 80 
Recipient dialysis twice in week prior 
to transplantation  
Yes 124 83 77 73 0.016 
No 2685 92 88 79 
Recipient viral status 
HBsAg 
  
Negative 2718 91 87 79 0.37 
Positive 288 93 88 83 
Co-existing HBV and delta virus  
  
Negative 575 89 84 73 0.017 
Positive 72 98 95 95 
Anti-HCV serology 
  
Negative 2193 92 89 83 <0.001 
Positive 754 88 82 67 
HIV serology 
  
Negative 2630 91 87 79 0.028 
Positive 45 91 76 66 
HCV RNA Negative 683 91 87 84 <0.001 
Positive 394 88 80 63 
Criteria for liver transplant 
Liver transplant urgency† Yes 164 84 81 79 0.038 
 No 1962 92 88 80  
UNOS status‡ 
  
  
  
1 247 88 83 80 <0.001 
2 413 84 79 73 
3 1756 93 89 81 
4 590 93 89 77 
UNOS status‡ 1 or 2  Yes 660 86 81 75 <0.001 
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No 2346 93 89 80 
MELD score ≤14 1326 93 88 77 0.47 
15–25 1159 91 87 81 
>25 521 89 85 79 
Liver function and laboratory values 
Recipient Child-Pugh class 
  
  
A 238 94 90 82 0.37 
B 695 93 90 81 
C 530 90 86 79 
Serum creatinine concentration 
≥2 mg/dL  
Yes 185 87 80 74 0.01 
No 2807 92 88 80 
Indication 
Main indication for transplant 
  
  
Acute liver failure 142 89 85 85 0.45 
Chronic liver 
disease 
1824 91 88 80 
Metabolic disease 141 89 86 78 
Tumor (benign) 63 95 88 84 
Tumor (malignant) 757 93 86 75 
Other 34 85 85 79 
Acute liver failure as main disease 
  
Yes 140 89 85 85 0.33 
No 2866 92 87 79 
Cirrhosis as main disease 
  
Yes 1648 91 88 79 0.86 
No 1358 92 87 79 
Cancer as main disease Yes 756 93 86 75 0.1 
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  No 2250 91 88 80 
Milan criteria (in patients with HCC) Yes 550 93 87 79 <0.001 
No 224 88 79 60 
HCC with tumor size >50 mm Yes 63 83 65 46 <0.001 
No 715 92 86 76 
Surgical procedure 
Total ischemia time  
  
  
>15 hours 17 82 82 82 0.39 
12–15 hours 128 84 79 78 
6–12 hours 2186 91 87 79 
0–6 hours 675 93 88 81 
Total ischemia time ≥12 hours Yes 145 84 80 78 0.47 
No 2861 92 88 79 
Type of graft 
  
  
  
  
Full size (donor 
brain death) 
2712 91 87 79 0.65 
Domino 28 93 85 65 
Living 77 87 83 83 
Reduced 13 92 92 92 
Split 116 93 92 85 
 After circulatory 
death 
60 94 87 87  
Liver transplant 
  
Heterotopic 4 100 67  0.003 
Orthotopic 2857 92 87 79 
Patient survival       
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Immunotherapy during Month 1 PR tacrolimus 1002 94 90 85 0.017 
IR tacrolimus  2004 92 88 80 
Donor characteristics 
Donor sex 
  
Female 1325 92 87 80 0.18 
Male 1665 93 89 83 
Donor age ≥50 years 
  
Yes 1776 91 86 78 <0.001 
No 1230 94 92 86 
Donor age ≥60 years 
  
Yes 1207 92 86 77 <0.001 
No 1799 93 90 84 
Macro/micro-vesicular graft steatosis No  597 93 91 85 0.039 
Yes 604 92 88 78 
Blood group compatibility 
  
Compatible 182 85 81 75 0.11 
Iso group 2799 93 89 82 
Non-compatible 23 90 83 83 
Recipient characteristics 
Recipient sex 
  
Female 951 93 90 83 0.021 
Male 2055 92 88 80 
Recipient age ≥50 years 
  
Yes 2065 92 88 79 0.001 
No 941 93 90 86 
Recipient age ≥60 years 
  
Yes 911 91 86 77 0.001 
No 2095 93 89 83 
Recipient dialysis (twice in week 
prior) 
Yes 124 83 77 73 0.002 
No 2685 93 89 82 
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Recipient viral status 
HBsAg 
  
Negative 2718 92 88 81 0.3 
Positive 288 94 90 85 
Co-existing HBV and delta virus  
  
Negative 575 90 85 76 0.025 
Positive 72 98 95 95 
Anti-HCV serology 
  
Negative 2193 93 90 84 <0.001 
Positive 754 89 83 71 
HIV serology 
  
Negative 2630 92 88 81 0.045 
Positive 45 91 80 70 
HCV RNA Negative 683 92 89 85 <0.001 
Positive 394 88 81 67 
Criteria for liver transplant 
Liver transplant urgency† Yes 164 84 84 81 0.099 
 No 1962 93 89 82  
UNOS status‡ 
  
  
  
1 247 89 85 82 <0.001 
2 413 85 81 74 
3 1756 94 90 83 
4 590 94 90 80 
UNOS status‡ 1 or 2  Yes 660 87 83 77 <0.001 
No 2346 94 90 82 
MELD score ≤14 1326 94 89 79 0.22 
15–25 1159 92 89 84 
>25 521 90 86 80 
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Liver function and laboratory values 
Recipient Child-Pugh class 
  
  
A 238 96 91 84 0.27 
B 695 94 91 83 
C 530 90 87 81 
Serum creatinine concentration 
≥2 mg/dL  
Yes 185 88 80 75 0.001 
No 2807 93 89 82 
Indication 
Main indication for transplant 
  
  
Acute liver failure 142 90 87 87 0.24 
Chronic liver 
disease 
1824 92 89 82 
Metabolic disease 141 90 87 78 
Tumor (benign) 63 95 92 89 
Tumor (malignant) 757 93 87 77 
Other 34 91 91 85 
Acute liver failure as main disease 
  
Yes 140 90 87 87 0.34 
No 2866 92 88 81 
Cirrhosis as main disease 
  
Yes 1648 92 89 82 0.61 
No 1358 93 88 81 
Cancer as main disease 
  
Yes 756 93 87 77 0.032 
No 2250 92 89 83 
Milan criteria (in patients with HCC) Yes 550 94 88 81 <0.001 
No 224 89 80 62 
HCC with tumor size >50 mm Yes 63 83 66 48 <0.001 
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No 715 93 87 78 
Total ischemia time  
  
  
>15 hours 17 82 82 82 0.31 
12–15 hours 128 85 80 79 
6–12 hours 2186 92 89 81 
0–6 hours 675 94 90 83 
Total ischemia time ≥12 hours Yes 145 85 80 79 0.26 
No 2861 93 89 81 
Type of graft 
  
  
  
  
Full size (donor 
brain death) 
2712 92 88 81 0.57 
Domino 28 93 89 69 
Living 77 89 89 89 
Reduced 13 100 100  
Split 116 94 93 88 
 After circulatory 
death 
60 98 91 86  
Liver transplant 
  
Heterotopic 4 100 67  0.001 
Orthotopic 2857 92 89 81 
*Log-rank p value for effect over 8 years. †Body-mass index was defined as underweight: <18.5 kg/m2, normal weight: 18.5–24.9 kg/m2, 
overweight: 25.0–29.9 kg/m2, obesity: ≥30 kg/m2. ‡Liver transplant urgency was determined by the treating physician and indicated on the 
questionnaire by ‘yes’ or ‘no’ tick box. §UNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous 
medical care, 4. At home with normal function. HBsAg: hepatitis B virus surface antigen; HBV: hepatitis B virus; HCC: hepatocellular 
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carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IR: immediate-release; MELD: Model for End-stage Liver Disease; PR: 
prolonged-release; UNOS: United Network for Organ Sharing 
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Table 4. Multivariate analyses of risk factors for reduced graft and patient survival for the 
propensity score-matched patients 
Risk factors at first transplant Risk ratio 95% confidence 
interval 
p value 
Graft survival    
Recipient anti-HCV serology positive 2.05 1.66–2.54 <0.001 
Recipient age ≥55 years 1.74 1.43–2.11 <0.001 
UNOS status* 1 or 2  1.69 1.35–2.11 <0.001 
Serum creatinine concentration ≥2 mg/dL 1.66 1.18–2.35 0.004 
IR tacrolimus immunotherapy 1.49 1.14–1.96 0.0038 
Donor age ≥50 years 1.35 1.09–1.66 0.0052 
Patient survival    
Recipient anti-HCV serology positive 1.91 1.52–2.40 <0.001 
Serum creatinine concentration ≥ 2 mg/dL 1.90 1.33–2.71 <0.001 
UNOS status* 1 or 2  1.89 1.49–2.39 <0.001 
Recipient age ≥55 years 1.74 1.41–2.16 <0.001 
IR tacrolimus immunotherapy 1.40 1.05–1.86 0.0215 
HCC (primary or secondary disease) 1.35 1.07–1.69 0.0109 
Donor age ≥50 years 1.33 1.07–1.66 0.0110 
*UNOS status 1: Hospitalized in the intensive care unit; 2: continuous hospitalization. 
N=3,883. HCC: hepatocellular carcinoma; HCV: hepatitis C virus; IR: immediate-release; 
UNOS: United Network for Organ Sharing 
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Table 5: Causes of graft loss and mortality over 8 years of treatment for the propensity score-matched patients 
Category Type Graft loss, n (%)  Mortality, n (%)  
All 
 
(n=3006) 
PR 
tacrolimus  
(n=1002) 
IR tacrolimus  
(n=2004) 
p 
value* 
All 
 
(n=3006) 
PR 
tacrolimus  
(n=1002) 
IR 
tacrolimus  
(n=2004) 
p 
value* 
Overall  408 93 315 – 351 82 269 – 
Technical 
complications 
 
All 44 (10.8) 12 (12.9) 32 (10.2) 0.45 19 (5.4) 6 (7.3) 13 (4.8) 0.38 
Biliary 21 (5.2) 6 (6.5) 15 (4.8) 0.39 12 (3.4) 4 (4.9) 8 (3.0) 0.41 
Vascular 24 (5.9) 6 (6.5) 18 (5.7) 0.79 8 (2.3) 2 (2.4) 6 (2.2) 1.00 
Rejection All 16 (3.9) 3 (3.2) 13 (4.1) 1.00 8 (2.3) 2 (2.4) 6 (2.2) 1.00 
Acute 5 (1.2) 1 (1.1) 4 (1.3) 1.00 3 (0.9) 1 (1.2) 2 (0.7) 0.55 
Chronic 11 (2.7) 2 (2.2) 9 (2.9) 1.00 5 (1.4) 1 (1.2) 4 (1.5) 1.00 
Non-tumoral 
recurrence 
 76 (18.6) 22 (23.7) 54 (17.1) 0.16 57 (16.2) 19 (23.2) 38 (14.1) 0.06 
Other liver 
complications 
 13 (3.2) 3 (3.2)  10 (3.2) 1.00 12 (3.4) 3 (3.7) 9 (3.4) 1.00 
Tumor Tumor 
recurrence 
49 (12.0) 13 (14.0) 36 (11.4) 0.51 48 (13.7) 13 (15.9) 35 (13.0) 0.51 
De novo tumor 50 (12.3) 10 (10.8) 40 (12.7) 0.62 50 (14.2) 10 (12.2) 40 (14.9) 0.54 
De novo tumor 
(lymph) 
3 (0.7) 1 (1.1) 2 (0.6) 0.54 3 (0.9) 1 (1.2) 2 (0.7) 0.55 
Infection Overall 109 (26.7) 28 (30.1) 81 (25.7) 0.40 107 (30.5) 27 (32.9) 80 (29.7) 0.58 
Bacterial 45 (11.0) 16 (17.2) 29 (9.2) 0.031 43 (12.3) 15 (18.3) 28 (10.4) 0.057 
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56 
Viral 1 (0.2) 0 1 (0.3) 1.00 1 (0.3) 0 1 (0.4) 1.00 
Fungal 2 (0.5) 1 (1.1) 1 (0.3) 0.40 2 (0.6) 1 (1.2) 1 (0.4) 0.41 
Undefined 67 (16.4) 13 (14.0) 54 (17.1) 0.47 66 (18.8) 12 (14.6) 54 (20.1) 0.27 
General Gastrointestinal 13 (3.2) 3 (3.2) 10 (3.2) 1.00 13 (3.7) 3 (3.7) 10 (3.7) 1.00 
Cardiovascular 18 (4.4) 5 (5.4) 13 (4.1) 0.57 18 (5.1) 5 (6.1) 13 (4.8) 0.58 
Cerebrovascular 13 (3.2) 6 (6.5) 7 (2.2) 0.08 13 (3.7) 6 (7.3) 7 (2.6) 0.09 
Renal 15 (3.7) 3 (3.2) 12 (3.8) 1.00 15 (4.3) 3 (3.7) 12 (4.5) 1.00 
Pulmonary 31 (7.6) 7 (7.5) 24 (7.6) 0.98 31 (8.8) 7 (8.5) 24 (8.9) 0.91 
Other  66 (16.2) 7 (7.5) 59 (18.7) 0.010 62 (17.7) 6 (7.3) 56 (20.8) 0.005 
Social cause  3 (0.7) 1 (1.1) 2 (0.6) 0.54 3 (0.9) 1 (1.2) 2 (0.7) 0.55 
Suicide  1 (0.2) 0 1 (0.3) 1.00 1 (0.3) 0 1 (0.4) 1.00 
*p value for Mantel–Haenszel Chi-Square between treatment cohort comparisons, or Fisher’s exact test, as appropriate. Data are presented for 
up to three causes of graft loss or patient mortality for each patient. IR: immediate-release; PR: prolonged-release
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FIGURE LEGENDS: 
Figure 1: Patient populations 
*Analysis only in centers using PR tacrolimus and IR tacrolimus. †Propensity score-
matching ratio 1:2, PR tacrolimus: IR tacrolimus. IR: immediate-release; mITT: 
modified intent-to-treat; PR: prolonged-release 
 
Figure 2: Kaplan–Meier analyses of (A) graft and (B) patient survival over 4 years of 
treatment with PR tacrolimus compared with IR tacrolimus, after exclusion of patients 
with <1 month of follow-up (mITT population) 
IR: immediate-release; mITT: modified intent-to-treat; PR: prolonged-release 
 
Figure 3: Kaplan–Meier analyses of (A) graft and (B) patient survival over 4 years of 
treatment in with PR tacrolimus compared with IR tacrolimus for the propensity 
score-matched patients 
IR: immediate-release; PR: prolonged-release 
 
Figure 4: Kaplan–Meier analyses of (A) graft and (B) patient survival over 4 years of 
treatment in crossover groups for the propensity score-matched patients 
IR: immediate-release; PR: prolonged-release 
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Table 5bis: Causes of graft loss and mortality over 8 years of treatment for the overall instance 
Category Type Graft loss, n (%)  Mortality, n (%)  
All 
 
(n=13088) 
PR 
tacrolimus  
(n=1762) 
IR  
tacrolimus  
(n=11326) 
p 
value* 
All 
 
(n=13088) 
PR 
tacrolimus  
(n=1762) 
IR 
tacrolimus  
(n=11326) 
p 
value* 
Overall  1618 157 1461 – 1370 138 1232 – 
Technical 
complications 
 
All 176 (10.9) 19 (12.1) 157 (10.8) 0.60 62 (4.5) 8 (5.8) 54 (4.4) 0.45 
Biliary 88 (5.4) 9 (5.7) 79 (4.9) 0.86 39 (2.9) 5 (3.6) 34 (2.8) 0.59 
Vascular 90 (5.6) 10 (6.4) 80 (5.5) 0.64 24 (1.8) 3 (2.2) 21 (1.7) 0.73 
Rejection All 87 (5.4) 5 (3.2) 82 (5.6) 0.20 49 (3.6) 4 (2.9) 45 (3.7) 0.81 
Acute 20 (1.2) 1 (0.6) 19 (1.3) 0.71 12 (0.9) 1 (0.7) 11 (0.9) 1.00 
Chronic 67 (4.1) 4 (2.6) 63 (4.3) 0.29 37 (2.7) 3 (2.2) 34 (2.8) 1.00 
Non-tumoral 
recurrence 
 225 (13.9) 26 (16.6) 199 (13.6) 0.31 176 (12.9) 23 (16.7) 153 (12.4) 0.16 
Other liver 
complications 
 84 (5.2) 5 (3.2)  79 (5.4) 0.23 56 (4.1) 4 (2.9) 52 (4.2) 0.46 
Tumor Tumor 
recurrence 
209 (12.9) 29 (18.5) 180 (12.3) 0.03 207 (15.1) 29 (21.0) 178 (14.5) 0.04 
De novo tumor 179 (11.1) 18 (11.5) 161 (11.0) 0.87 179 (13.1) 18 (13.0) 161 (13.1) 0.99 
De novo tumor 
(lymph) 
18 (1.1) 2 (1.3) 16 (1.1) 0.69 18 (1.3) 2 (1.5) 16 (1.3) 0.70 
Infection Overall 424 (26.2) 53 (33.8) 371 (25.4) 0.02 410 (29.9) 49 (35.5) 361 (29.3) 0.13 
Bacterial 208 (12.9) 33 (21.0) 175 (12.0) 0.001 195 (14.2) 30 (21.7) 165 (13.4) 0.01 
Additional File For Information Only - not published or cited in text
2 
 
Viral 9 (0.6) 1 (0.6) 8 (0.6) 0.60 9 (0.7) 1 (0.7) 8 (0.7) 1.00 
Fungal 23 (1.4) 2 (1.3) 21 (1.4) 1.00 21 (1.5) 1 (0.7) 20 (1.6) 0.71 
Undefined 220 (13.6) 24 (15.3) 196 (13.4) 0.52 219 (16.0) 23 (16.7) 196 (15.9) 0.82 
General Gastrointestinal 54 (3.3) 8 (5.1) 46 (3.2) 0.20 52 (3.8) 8 (5.8) 44 (3.6) 0.19 
Cardiovascular 92 (5.7) 8 (5.1) 84 (5.8) 0.74 92 (6.7) 8 (5.8) 84 (6.8) 0.65 
Cerebrovascular 48 (3.0) 7 (4.5) 41 (2.8) 0.22 48 (3.5) 7 (5.1) 41 (3.3) 0.32 
Renal 30 (1.9) 3 (1.9) 27 (1.9) 1.00 30 (2.2) 3 (2.2) 27 (2.2) 1.00 
Pulmonary 107 (6.6) 7 (4.5) 100 (6.8) 0.25 107 (7.8) 7 (5.1) 100 (8.1) 0.21 
Other  239 (14.8) 11 (7.0) 228 (15.6) 0.004 220 (16.1) 8 (5.8) 212 (17.2) 0.0005 
Social cause  16 (1.0) 1 (0.6) 15 (1.0) 1.00 16 (1.2) 1 (0.7) 15 (1.2) 1.00 
Suicide  7 (0.4) 0 7 (0.5) 1.00 7 (0.5) 0 7 (0.6) 1.00 
*p value for Mantel–Haenszel Chi-Square between treatment cohort comparisons, or Fisher’s exact test, as appropriate. Data are presented for  
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